IL158131A0 - Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism - Google Patents

Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism

Info

Publication number
IL158131A0
IL158131A0 IL15813102A IL15813102A IL158131A0 IL 158131 A0 IL158131 A0 IL 158131A0 IL 15813102 A IL15813102 A IL 15813102A IL 15813102 A IL15813102 A IL 15813102A IL 158131 A0 IL158131 A0 IL 158131A0
Authority
IL
Israel
Prior art keywords
compositions
compounds
methods
fatty acid
body fat
Prior art date
Application number
IL15813102A
Other languages
English (en)
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of IL158131A0 publication Critical patent/IL158131A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
IL15813102A 2001-03-27 2002-03-27 Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism IL158131A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27954201P 2001-03-27 2001-03-27
US33628901P 2001-10-31 2001-10-31
PCT/US2002/009773 WO2002080860A2 (en) 2001-03-27 2002-03-27 Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism

Publications (1)

Publication Number Publication Date
IL158131A0 true IL158131A0 (en) 2004-03-28

Family

ID=26959730

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15813102A IL158131A0 (en) 2001-03-27 2002-03-27 Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism

Country Status (11)

Country Link
US (3) US6911474B2 (enExample)
EP (1) EP1408945A4 (enExample)
JP (1) JP2004526745A (enExample)
KR (1) KR20030087657A (enExample)
CN (1) CN1523982A (enExample)
AU (1) AU2002338329B2 (enExample)
CA (1) CA2442683A1 (enExample)
EA (1) EA006556B1 (enExample)
IL (1) IL158131A0 (enExample)
MX (1) MXPA03008823A (enExample)
WO (1) WO2002080860A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030087657A (ko) 2001-03-27 2003-11-14 더 리전츠 오브 더 유니버시티 오브 캘리포니아 체지방 감소 및 지방산 대사 조절을 위한 방법, 화합물 및조성물
DE10129693A1 (de) * 2001-06-22 2003-01-02 Jan Loock Verfahren zur extrakorporalen qualitativen und/oder quantitativen Erfassung neurotoxischer Substanzen im Blutplasma eines Individuums
ES2297176T5 (es) 2002-02-12 2011-12-07 HUNZA DI PISTOLESI ELVIRA & C. S.A.S. Composiciones que contienen n-acil-fosfatidil-etanolaminas y/o mezclas de n-acil-etanolaminas con ácidos fosfatídicos o ácidos lisofosfatídicos.
AU2003296895A1 (en) * 2002-08-20 2004-05-04 The Regents Of The University Of California Combination therapy for controlling appetites
US7765162B2 (en) * 2002-10-07 2010-07-27 Mastercard International Incorporated Method and system for conducting off-line and on-line pre-authorized payment transactions
AU2003290387A1 (en) * 2002-11-18 2004-06-15 Natural Asa Dietry supplements and foods product comprising oleylethanolamide
US7083933B1 (en) 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
EP1677780A4 (en) * 2003-10-16 2007-05-02 Univ California DIETARY AND OTHER FOODS, COMPOUNDS AND METHOD FOR REDUCING BODY FAT, APPETIZING AND MODULATING THE FATTY ACID CHANGES
ATE399474T1 (de) * 2004-03-06 2008-07-15 Cognis Ip Man Gmbh Use of unsaturated fatty acids for the reduction of appetite or food intake
JP2006061086A (ja) * 2004-08-27 2006-03-09 Morishita Jintan Kk 脂肪代謝改善効果を有する被験試料のスクリーニング方法
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US20090054526A1 (en) * 2005-07-14 2009-02-26 Hansen Harald S Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
PE20071221A1 (es) * 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
ES2354390T3 (es) 2006-04-11 2011-03-14 Arena Pharmaceuticals, Inc. Procedimientos de uso del receptor gpr119 para identificar compuestos útiles para aumentar la masa ósea en un individuo.
US20090208513A1 (en) * 2007-09-07 2009-08-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Diagnostic And Therapeutic Uses Of Augmenter Of Liver Regeneration In Inflammatory Conditions
ES2291147B1 (es) * 2007-10-15 2008-11-01 Fundacion Instituto Mediterraneo Para La Biotecnologia Y La Investigacion Sanitaria (Imabis) Derivados pirazolicos de amidas de acidos grasos como activadores especificos de receptores ppar-alfa, procedimiento de preparacion y utilizacion.
EP2146210A1 (en) * 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
US20090264520A1 (en) * 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
CN102036559A (zh) * 2008-05-19 2011-04-27 雀巢产品技术援助有限公司 降低动物脂质吸收的方法
US20130122147A1 (en) * 2010-03-24 2013-05-16 Delphine Chaillot Tissot-Favre Methods for enhancing the palatability of comestible compositions
WO2012003176A1 (en) 2010-07-02 2012-01-05 Helix Biomedix, Inc. N-acyl amino acid derivatives for treating skin conditions such as cellulite
WO2012099942A2 (en) 2011-01-19 2012-07-26 Terakine Therapeutics, Inc. Methods and compositions for treating metabolic syndrome
US20140193370A1 (en) * 2011-05-10 2014-07-10 Nestec Sa Methods and compositions for promoting lean body mass growth
BR112013028759A2 (pt) * 2011-05-10 2016-08-09 Nestec Sa métodos e composições para conservar a massa magra do corpo durante a perda de peso
US8426471B1 (en) * 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
CN102579414A (zh) * 2012-01-29 2012-07-18 厦门大学 油酰乙醇胺作为降血脂、防治非酒精性脂肪肝药物的用途
WO2013160492A1 (es) * 2012-04-24 2013-10-31 Fundación Instituto Mediterráneo Para El Avance De La Biotecnología Y La Investigación Sanitaria (Imabis) Terapia combinada para el tratamiento de enfermedades metabólicas
US9221747B2 (en) 2012-04-25 2015-12-29 Iowa State University Research Foundation, Inc. Method of making fatty acid N-acylalkanolamines
CN102675141A (zh) * 2012-05-04 2012-09-19 庄信修 N-(2-羟基乙基)芥酰胺及其制备与用途
CN104602536A (zh) 2012-09-07 2015-05-06 雀巢产品技术援助有限公司 油酰乙醇胺组合物
CN102824338A (zh) * 2012-09-18 2012-12-19 厦门大学 s-油酰丙醇胺在制备降血脂、防治非酒精性脂肪肝药物中的用途
JP5877620B2 (ja) 2012-11-21 2016-03-08 トポカイン セラピューティックス， インコーポレイテッド 体脂肪を局所的に増大させるための方法および組成物
CN103113253A (zh) * 2013-01-28 2013-05-22 国家海洋局第三海洋研究所 一种不饱和脂肪酸醇胺衍生物及其制备方法与应用
ES2498521B1 (es) * 2013-02-20 2015-08-18 Fundación Pública Andaluza Para La Investigación De Málaga En Biomedicina Y Salud (Fimabis) Formulaciones basadas en nanoemulsiones y su uso para el tratamiento de la obesidad
NO2753788T3 (enExample) 2013-05-10 2018-06-16
WO2014186504A1 (en) 2013-05-15 2014-11-20 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
WO2015200425A1 (en) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Topical dosage regimen
MY172113A (en) 2017-07-05 2019-11-14 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US10702487B2 (en) 2017-08-19 2020-07-07 Frimline Private Limited Pharmaceutical composition for prevention of diet induced obesity
MY186286A (en) 2017-09-05 2021-07-05 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of chronic kidney disease
WO2024124172A1 (en) * 2022-12-09 2024-06-13 The Trustees Of The University Of Pennsylvania Compositions and methods for stimulating and/or enhancing exercise motivation and/or physical performance

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8505569D0 (sv) * 1985-11-25 1985-11-25 Aco Laekemedel Ab Enteralt preparat
US5506224A (en) * 1991-12-31 1996-04-09 Lifegroup S.P.A. N-acyl derivatives of aminoalcohols active as local autacoids and useful in the therapy of autoimmune processes
US5679667A (en) * 1992-04-24 1997-10-21 Lifegroup S.P.A. Aminoalcohols-N-Acyl derivatives as therapeutical agents against the neurogenic endoneural edema of the peripheral nerve
US5602164A (en) * 1992-04-28 1997-02-11 Senyorina Ltd. Anti-obesity drugs
US5554646A (en) * 1992-04-29 1996-09-10 Wisconsin Alumni Research Foundation Method for reducing body fat in animals
IL103932A (en) 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
US5618955A (en) * 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
US5631297A (en) * 1994-07-11 1997-05-20 Pate; David W. Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
IT1271266B (it) * 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
IT1274783B (it) * 1994-12-15 1997-07-24 Antonio Picarelli Preparato per il trattamento dell'obesita'
AU5524896A (en) * 1995-03-20 1996-10-08 Institut Pasteur De Lille Modulators of ob gene and screening methods therefor
US6271015B1 (en) 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
US6090836A (en) 1996-02-02 2000-07-18 Merck & Co., Inc. Benzisoxazole-derived antidiabetic compounds
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
DE69728267T2 (de) 1996-02-02 2005-02-24 Merck & Co., Inc. Antidiabetisches mittel
US5847008A (en) 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US5803916A (en) 1996-03-19 1998-09-08 Vital-Tech Ltd. Body and joints massage device
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
US5830916A (en) * 1996-05-23 1998-11-03 Duke University Inhibitor of ceramidase
US5856537A (en) 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
US5925672A (en) 1996-12-06 1999-07-20 Neurosciences Research Foundation, Inc. Methods of treating mental diseases, inflammation and pain
US6090839A (en) 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
US6160000A (en) 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
US5985282A (en) * 1997-01-22 1999-11-16 Hpf, L.L.C. Herbal appetite suppressant and weight loss composition
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6008237A (en) 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
WO1999060987A2 (en) 1998-05-29 1999-12-02 Neurosciences Research Foundation, Inc. Control of pain with endogenous cannabinoids
US7897598B2 (en) 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US6274608B1 (en) 1999-04-20 2001-08-14 Novo Nordisk A/S Compounds, their preparation and use
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
US6359010B1 (en) * 1999-11-23 2002-03-19 Thomas D. Geracioti, Jr. Methods of treating anxiety and mood disorders with oleamide
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
EP1294411A4 (en) 2000-05-23 2006-02-01 Univ California COUGH TREATMENT
KR20030087657A (ko) 2001-03-27 2003-11-14 더 리전츠 오브 더 유니버시티 오브 캘리포니아 체지방 감소 및 지방산 대사 조절을 위한 방법, 화합물 및조성물
US7048941B2 (en) 2001-03-30 2006-05-23 New World Enterprizes, Inc. Chocolate composition as delivery system for nutrients and medications
AU2002309548B2 (en) * 2001-04-06 2006-08-10 The Board Of Trustees Of The University Of Illinois Functional role for cannabinoids in autonomic stability during sleep
US7351874B2 (en) * 2001-07-31 2008-04-01 The Scripps Research Institute Mouse model for fatty acid amide-related neurobehaviors
WO2003065989A2 (en) 2002-02-08 2003-08-14 Bristol-Myers Squibb Company (oxime)carbamoyl fatty acid amide hydrolase inhibitors
AU2003290387A1 (en) 2002-11-18 2004-06-15 Natural Asa Dietry supplements and foods product comprising oleylethanolamide

Also Published As

Publication number Publication date
MXPA03008823A (es) 2004-08-12
EP1408945A2 (en) 2004-04-21
US6911474B2 (en) 2005-06-28
EA006556B1 (ru) 2006-02-24
AU2002338329B2 (en) 2006-09-07
US7423066B2 (en) 2008-09-09
EA200301057A1 (ru) 2004-04-29
AU2002338329C1 (en) 2002-10-21
CN1523982A (zh) 2004-08-25
US20090005447A1 (en) 2009-01-01
CA2442683A1 (en) 2002-10-17
WO2002080860A3 (en) 2004-02-26
US20050187254A1 (en) 2005-08-25
KR20030087657A (ko) 2003-11-14
US20030018081A1 (en) 2003-01-23
JP2004526745A (ja) 2004-09-02
EP1408945A4 (en) 2005-07-06
WO2002080860A2 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
IL158131A0 (en) Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
AU2003274652A8 (en) Compounds, compositions and methods for modulating fat metabolism
AU2002342968A1 (en) Fatty acid compounds, preparation and uses thereof
AU2002366804A1 (en) Methods to reduce body fat
HUP0401343A3 (en) Compositions containing coenzyme q and eicosapentaenoic acid (epa) and their use
AU2003251557A1 (en) Fat compositions for infant formula and methods therefor
EP1186648A4 (en) FAT COMPOSITION
WO2002064129A3 (en) Compositions of biochemical compounds involved in bioenergy metabolism of cells
AU2003287443A8 (en) Compositions and methods for pain reduction
EP1461047A4 (en) COMPOSITIONS AND METHODS FOR TREATING ANIMALS
EP1557090A4 (en) FAT COMPOSITION FOR A PANEL PRODUCT
AU2002253018A1 (en) Skin composition for reducing skin oils and grease
EP1431379A4 (en) PROCESS FOR THE PRODUCTION OF FATTY COMPOSITIONS CONTAINING OLEANOLIC ACID AND / OR MASLINIC ACID
AU2003266138A8 (en) Multi-use vessels for vitamin d formulations
AU2003287584A8 (en) Conjugated fatty acid based emulsion and methods for preparing and using same
AU4726401A (en) Micronized vitamin c formulation
EP1538897A4 (en) METHOD FOR CHANGING THE FATTY SURFACE COMPOSITION OF MILK
GB0006865D0 (en) Low pH high fatty acid vanishing cream
GB0006866D0 (en) Low Ph high fatty acid vanishing cream
SG93225A1 (en) Higher unsaturated fatty acid composition
MXPA03004817A (es) Composicion dietetica conteniendo acido linoleico conjugado y calcio para salud mejorada.
AU2002216704A1 (en) Compositions having comfrey and methods for reducing retinoid-induced skin irritation
GB0120415D0 (en) Palatable high fat composition
GB0129987D0 (en) Skin compositions
AU4912801A (en) Methods and compositions for dietary supplements